Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors.

ABSTRACT:

Background

Intravesical BCG is the gold-standard therapy for non-muscle invasive bladder cancer (NMIBC); however, it still fails in a significant proportion of patients, so improved treatment options are urgently needed.

Methods

Here, we compared BCG antitumoral efficacy with another live attenuated mycobacteria, MTBVAC, in an orthotopic mouse model of bladder cancer (BC). We aimed to identify both bacterial and host immunological factors to understand the antitumoral mechanisms behind effective bacterial immunotherapy for BC.

Results

We found that the expression of the BCG-absent proteins ESAT6/CFP10 by MTBVAC was determinant in mediating bladder colonization by the bacteria, which correlated with augmented antitumoral efficacy. We further analyzed the mechanism of a

SUBMITTER: Moreo E 

PROVIDER: S-EPMC9252205 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature